Release of histamine by H2-receptor antagonists by Parkin, J. V. et al.
938
Once an adrenal origin has been excluded the treatments available
for PCO are temporary or symptomatic. Clomiphene can only be
used short term under well-controlled conditions in women who
want to have children. Anti-androgens can suppress hirsutism but
their long-term effects are unknown and they do have to be taken
continuously. Only wedge excision of both ovaries permits a full
resumption of ovarian function (normal ovulatory cycles) which has
been found to be temporary by some workers and long-lasting by
others. A major disadvantage of bilateral wedge excision is the
formation of pelvic adhesions which may be responsible for
iatrogenic sterility in 30% of women treated in this way.
On the assumption that numbers of androgen-producing cells
could also be much reduced by unilateral oophorectomy (a shorter
and easier operation than the bilateral wedge procedure), we have
removed one ovary in ten patients with PCO.
In all ten patients adrenal disease was rulled out and the ovaries
were clearly unequal in size. However, the unequal size was not
always confirmed at laparotomy-in one case the ovaries were equal
in size and in another the contralateral ovary turned out to be the
larger one. The policy was to remove the larger ovary.
Postoperatively blood testosterone levels fell in all patients and
became normal in eight. A regular ovulatory cycle developed
immediately after surgery in all patients.
In five patients the indication for treatment was infertility and
attempts to restore fertility with clomiphene had failed. Three of
these patients, who were operated on in 1980, conceived within 6
months and have been delivered of healthy full-term babies. The
remaining two patients were operated on very recently.
Echography has revealed that the remaining ovary has become
normal in size and that the microcysts have disappeared. The
hypertrichosis, present in all ten patients, has not got worse. There
have been no new sites of hair growth and shaving and other hair
removal techniques have usually been applied less frequently. At
the request of one patient she was given anti-androgens. One patient
who has had severe premenstrual tension and heavy periods after
surgery regrets having decided to have the operation.
After a mean follow-up of 30 months there have been no relapses
of PCO and all ten women still have regular ovulatory cycles. Blood
testosterone levels have risen slightly in two patients.
This pilot study suggests that simple unilateral oophorectomy can
probably replace bilateral wedge excisions from ovaries in patients
with PCO.
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INTRACAVERNOUS INJECTION OF PAPAVERINE FOR
ERECTILE FAILURE
SIR,-The mechanism for the filling of the cavernous bodies at the
onset of erection is still in disputes Accidental intracavernous
injection of papaverine during a surgical shunting procedure2
produced a prolonged fully rigid erection of two hours’ duration.
This fact, combined with observation of improvement of erectile
function reported by impotent patients after they had been
subjected to artificial erection for evaluation of erectile
dysfunction,4 led us to study the effect of intracavernous injection
of papaverine.
The study was done after the thorough investigations (including
nocturnal penile tumescence monitoring, pudendal arteriography,
and bulbocavernous reflex latency measurements) that we
recommend for evaluation of erectile dysfunction.3,4 In this way we
could classify cases as organic or non-organic impotence.
80 mg papaverine was injected into one of the cavernous bodies,
after insertion into the other of a 21 G plastic needle for continuous
1. Wagner G, Bro Rasmussen F, Willis EA, Nielsen MH. New theory on the mechanism
of erection involving hitherto undescribed vessels. Lancet 1982; 1: 416-18.
2. Michal V, Kramar R, Pospichal J. Arterial epigastrico cavernous anastomosis for the
treatment of sexual impotence. World J Surg 1977; 1: 515-20.
3. Virag R, Zwang G, Dermange H, Legman M. Utilisation de l’erection passive dans
l’exploration de l’impuissance d’origine vasculaire. Contracept Fertil Sexual 1979; 7:
707-10.
4. Virag R, Zwang G, Dermange H, Legman M. Vasculogenic impotence: a review of 92
cases with 54 surgical operations. Vasc Surg 1981; 15: 9-17.
monitoring of intracavernous pressure (ICP). To study the
condition of the arterial vessels, ultrasonic continuous measurement
(Doppler method) and pulse plethysmography were used. Later,
selective bilateral internal iliac arteriography was done. Our
preliminary findings relate to fifteen organic cases and ten
non-organic cases of impotence.
The immediate reaction was an increase in ICP, indicating
volume changes and the development of pressure inside the
cavernous bodies. The mean value of the ICP increase was much
higher when the trial was done during general anaesthesia (mean
ICP increase 70 mm Hg compared with 40 mm Hg without anaes-
thesia). This effect was related to increased arterial flow, as shown
by Doppler studies, plethysmography, and arteriography. The peak
effect, depending on the state of the arteries, was obtained after
2-15 min, and an effect lasted for from 10 to 120 min. There were
no general or local complications.
Seven of the fifteen patients with an organic aetiology reported
significantly improved erections in the days after the procedure, but
none of the non-organic cases reported any changes in their erectile
capability. All seven had arterial lesions in the distal part of the
internal pudendal artery and/or in the cavernous arteries.
In the light of these results thirty impotent patients (including
twelve with diabetes mellitus) who had Doppler and arteriographic
evidence of arterial insufficiency were selected for conservative
therapy. Intracavernous injection of papaverine (80 mg) was
followed, after 15 min observation of the drug’s effect, by infusion
of 1% heparin in normal saline via an infusion pump, to obtain and
maintain a rigid erection for a 15 min period. No anaesthesia was
used.
The procedure was repeated 2 months later and then every third
month or according to the clinical status. Of the fourteen patients
(seven with diabetes) who had two or more artificial erections, four
reported a return to a normal sexual life; nine described a significant
improvement in penile rigidity; in one there was no effect and an
arterial revascularisation procedure was done.
Few clinical studies have been done on the effects of drugs on
penile erection.5 No vasoactive drug has proved effective in con-
trolled studies. Papaverine is a powerful smooth-muscle relaxant
and has been used in laboratory studies of vasoactive drugs, as a
control substance. 6 Two levels of action seem possible: inhibition of
cyclic AMP phosphodiesterase or an antinicotinic effect. 8
Artificial erections achieved with normal saline are associated with
vasodilatation of branches of the pudendal arteries,9 and we agree
that there must be mechanical action at the level of the cavernous
tissue.
I thank Dr Gorm Wagner, Panum Institute, University of Copenhagen, for
comments.
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RELEASE OF HISTAMINE BY H2-RECEPTOR
ANTAGONISTS
SIR,-There has been a good deal of debate in The Lancet lately
about cardiac effects of H2-receptor antagonists. Earlier reports of
cardiac dysfunction have largely concerned intravenous
cimetidine.’ We report here findings with both cimetidine and
ranitidine given intravenously (i.v.).
The study followed a chance observation. We were investigating
the release of histamine by plasma substitutes and seeking to
prevent adverse effects. Before infusion of the plasma substitute
5. Wagner G, Green R. Impotence, physiological, psychological, and surgical diagnosis
and treatment. New York: Plenum Press, 1981.
6. Betz E, Ingvar DH. Regional blood flow in the cerebral cortex measured by heat and
inert gas clearance. Acta Physiol Scand 1967; 1: 1-9.
7. Posch G, Kukometz WR. Papaverine induced inhibition of phosphodiesterase activity
in various mammalian tissues. Life Sci 1969; 10: 133-44.
8. Bauer V, Caper R. Studies on the neuropharmacology of papaverine
Neuropharmacology 1972; 11: 697-700.
9. Michal V, Pospichal J. Phalloarteriography in the diagnosis of corpus cavernosography
Radiology 1976; 119: 69-73.
1. Cohen J, Weetman AP, Darjie HJ, Krikler DM. Life-threatening arrhythmias and
intravenous cimetidine. Br Med J 1979; ii. 768.
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TABLE I-INCREASE IN PLASMA HISTAMINE LEVELS (ng/ml):
FIRST STUDY
TABLE II-INCREASE IN PLASMA HISTAMINE LEVELS (ng/ml):
SECOND STUDY
some subjects were given i.v. saline, some i.v. cimetidine, and some
both cimetidine and chlorpheniramine. Blood was taken for plasma
histamine assay by a fluorimetric method2 which, because it does
not depend on histamine methyltransferase, is valid in the presence
of cimetidine and ranitidine. After cimetidine 10 mg/kg two subjects
showed a rise in plasma histamine of more than 1 ng/ml (table I),
giving levels which can produce cardiac arrhythmias in susceptible
subjects.3 When both cimetidine and chlorpheniramine were used
four of the seven subjects showed a rise of at least 1 ng/ml. These
results were worrying, but the cimetidine dosage was much greater
than the conventional clinical dose and had been chosen on the basis
of animal studies. We decided to investigate this further, using
normal clinical doses of both ranitidine and cimetidine.
Ten subjects were given cimetidine 200 mg or ranitidine 80 mg
i.v. over 30 s on consecutive days in a single-blind study. The order
of the drugs was randomised. The study was confined to doctors
who were fully informed of the nature and hazards of the
investigation.
Satisfactory samples were obtained from nine doctors but in the
tenth blood sampling was difficult and subsequent haemolysis made
the proper preparation of plasma samples impossible. None of the
nine subjects showed a plasma histamine rise of 1 ng/ml, nor was
there any subjective evidence of histamine release.4 4
We conclude that there is a risk of a dangerous rise in plasma
histamine if a high dose of cimetidine (and, possibly, other
Hz-receptor blocking agents) is given by rapid i.v. injection.
However, standard doses of cimetidine or ranitidine given by slow
i.v. injection do not have this effect. The data sheets produced by
Smith, Kline and French and Glaxo, respectively, emphasise the
need for slow i.v. injection but casual observation suggests that the
2. Lorenz W, Reimann HJ, Barth H, et al. A sensitive and specific method for the
determination of histamine in human whole blood and plasma. Hoppe-Seyler Z
Physiol Chem 1972; 353: 911-20.
3 Levi R, Allen G. Histamine mediated cardiac effects. In: Bristow M, ed. Drug induced
heart disease. Amsterdam: Elsevier/North Holland Biomedical Press, 1980:
377-95.
4. Lorenz W, Doenicke A, Schoening B, Neugebauer E. The role of histamine in adverse
reactions to intravenous agents. In: Thornton JA, ed. Adverse reactions of
anaesthetic drugs. Amsterdam: Elsevier/North Holland Biomedical Press, 1981:
169-238
importance of this is not widely appreciated. Our studies suggest
that injection over 30 s into a peripheral vein is safe. We have no
information about the effects of Hz-receptor antagonists given into
central venous lines, but it seems reasonable to suppose that this
route may be particularly hazardous.
We have not identified the source of the histamine which can be
released under these circumstances. However, human myocardial
tissue contains approximately JOOO ng of histamine per g wet
weight. The release of only a small proportion of this histamine
could give rise to severe cardiac arrhythmia3 and the exact form of
such cardiac effects seems likely to be unpredictable, especially if
histamine receptors are already partly antagonised.
We thank Glaxo Group Research Ltd for the gift of ranitidine and for
financial support for this study.
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LACK OF RESPONSE TO INTRAVENOUS CALCIUM IN
SEVERE VERAPAMIL POISONING
SIR,-Verapamil is a slow calcium channel blocker which
depresses sinus and atrioventricular node activity as well as
producing a negative inotropic effect on the myocardium. Although
this drug has been available for 20 years, only thirteen reports (seven
in English6-12) of poisoning have been published, three of which
include supporting analytical data. 6,7,12 We report here the most
severe case of verapamil poisoning so far described.
A 39-year-old woman was admitted unconscious (grade 3 coma)
after a presumed overdose. On admission she had an unrecordable
blood pressure and bradycardia (48/min), but there were no focal
neurological signs; ventilation was adequate after endotracheal
intubation. An ECG showed alternating junctional and sinus
rhythm with abnormal intraventricular conduction, first-degree
heart block (PR 0-44 s) and negative P waves. There was
-circumstantial evidence of acute beta-adrenergic blocking drug
overdosage so glucagon 10 mg, prenalterol 10 mg, and atropine 1’ 2
mg were given intravenously, but without improvement. Because of
marked hypotension and anuria, infusions of dopamine (2 - 5
tg/kg/min), frusemide (2 mg/min), and dobutamine (increasing
doses to 40 g/kg/min) were started. 90 min after admission it was
learned that the patient had ingested at least 1200 mg verapamil up
to 18 h before admission, and this was confirmed analytically13
(figure). Calcium gluconate (10%) 20 rnl was given intravenously
and within 30 min the intraventricular conduction abnormality
became less marked. Thereafter calcium gluconate (10%) was
infused to a total of 240 ml over 44 h, as an adjunct to other
supportive measures. Despite the dobutamine infusion the blood
pressure remained unrecordable and bradycardia persisted. An
infusion of isoprenaline (5 mg over 30 min) was therefore started
and continued at a rate of 2 pig/niin. Within 15 min the pulse was
80/min and the blood pressure 90/60 mm Hg. Subsequently, on
withdrawal of dobutamine, it was necessary to increase the dose of
5. Griswood RW, Lincoln JCR, Owen DAA. Effects of histamine on human isolated heart
muscle: comparison with effects on noradrenaline. J Pharm Pharmacol 1980; 32:
145-46.
6. Perkins CM. Serious verapamil poisoning: Treatment with intravenous calcium
gluconate. Br Med J 1978; ii: 1127.
7. Woie L, Storstein L. Successful treatment of suicidal verapamil poisoning with calcium
gluconate. Europ Heart J 1981; 2: 239-42.
8. Moroni F, Mannaioni PF, Dolara A, Ciaccheri M. Calcium gluconate and hypertonic
sodium chloride in a case of massive verapamil poisoning. Clin Toxicol 1980; 17:
395-400.
9. Candell J, Valle V, Soler M, Rius J. Acute intoxication with verapamil. Chest 1979; 75:
200-01.
10. De Faire U, Lundman T. Attempted suicide with verapamil. Europ J Cardiol 1977; 6:
195-98.
11. Da Silva OA, De Melo RA, Filho JPJ. Verapamil acute self-poisoning. Clin Toxicol
1979; 14: 361-67.
12. Gelbke HP, Schlicht HJ, Schmidt Gg Fatal poisoning with verapamil. Arch Toxicol
1977; 37: 89-94.
13. Cole SCJ, Flanagan RJ, Johnston A, Holt DW Rapid high-performance liquid
chromatographic method for the measurement of verapamil and norverapamil in
blood plasma or serum. J Chromatogr 1981; 218: 621-29.
